Mark Halliday

2.3k total citations · 2 hit papers
14 papers, 1.8k citations indexed

About

Mark Halliday is a scholar working on Molecular Biology, Cell Biology and Physiology. According to data from OpenAlex, Mark Halliday has authored 14 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Cell Biology and 5 papers in Physiology. Recurrent topics in Mark Halliday's work include Prion Diseases and Protein Misfolding (10 papers), Endoplasmic Reticulum Stress and Disease (7 papers) and Alzheimer's disease research and treatments (4 papers). Mark Halliday is often cited by papers focused on Prion Diseases and Protein Misfolding (10 papers), Endoplasmic Reticulum Stress and Disease (7 papers) and Alzheimer's disease research and treatments (4 papers). Mark Halliday collaborates with scholars based in United Kingdom, Australia and Switzerland. Mark Halliday's co-authors include Giovanna R. Mallucci, Helois Radford, Nicholas Verity, Julie A. Moreno, David A. Barrett, Anne E. Willis, Colin Molloy, Catharine A. Ortori, Martin Bushell and Jeffrey M. Axten and has published in prestigious journals such as Nature, Analytical Chemistry and Brain.

In The Last Decade

Mark Halliday

14 papers receiving 1.7k citations

Hit Papers

Sustained translational repression by eIF2α-P mediates pr... 2012 2026 2016 2021 2012 2013 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sustained translational repression by eIF2α-P mediates prion neurodegeneration
    2012 489 citations Julie A. Moreno, Helois Radford et al. Nature profile →
  2. Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice
    2013 453 citations Julie A. Moreno, Mark Halliday et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Halliday United Kingdom 11 1.1k 859 429 376 297 14 1.8k
Helois Radford United Kingdom 11 1.3k 1.2× 921 1.1× 489 1.1× 379 1.0× 315 1.1× 12 2.1k
Nicholas Verity United Kingdom 11 1.2k 1.1× 932 1.1× 521 1.2× 388 1.0× 346 1.2× 12 2.0k
Riccardo Cristofani Italy 25 926 0.8× 445 0.5× 243 0.6× 530 1.4× 350 1.2× 47 1.9k
Rand Posmantur United States 21 1.3k 1.2× 706 0.8× 290 0.7× 437 1.2× 525 1.8× 26 2.4k
John Labbadia United Kingdom 9 850 0.8× 281 0.3× 303 0.7× 383 1.0× 336 1.1× 11 1.5k
Cristina Caballero Spain 14 499 0.5× 280 0.3× 622 1.4× 246 0.7× 313 1.1× 34 1.5k
Colin Molloy United Kingdom 9 561 0.5× 372 0.4× 230 0.5× 161 0.4× 185 0.6× 11 988
Salvatore J. Cherra United States 14 1.1k 1.0× 318 0.4× 483 1.1× 929 2.5× 364 1.2× 20 2.1k
Kie Itoh United States 18 1.2k 1.1× 233 0.3× 271 0.6× 377 1.0× 189 0.6× 31 1.6k
Olaf Goldbaum Germany 22 696 0.6× 250 0.3× 398 0.9× 180 0.5× 236 0.8× 24 1.2k

Countries citing papers authored by Mark Halliday

Since Specialization
Citations

This map shows the geographic impact of Mark Halliday's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Halliday with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Halliday more than expected).

Fields of papers citing papers by Mark Halliday

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Halliday. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Halliday. The network helps show where Mark Halliday may publish in the future.

Co-authorship network of co-authors of Mark Halliday

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Halliday. A scholar is included among the top collaborators of Mark Halliday based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Halliday. Mark Halliday is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Kandanaarachchi, Sevvandi, David Alexánder, Benjamin W. Muir, et al.. (2023). Comparison of Tiling Artifact Removal Methods in Secondary Ion Mass Spectrometry Images. Analytical Chemistry. 95(47). 17384–17391. 1 indexed citations
2.
Albert‐Gascó, Héctor, Heather Smith, Beatriz Alvarez‐Castelao, et al.. (2023). Trazodone rescues dysregulated synaptic and mitochondrial nascent proteomes in prion neurodegeneration. Brain. 147(2). 649–664. 9 indexed citations
3.
Hughes, Daniel T., Mark Halliday, Heather Smith, et al.. (2020). Targeting the kinase insert loop of PERK selectively modulates PERK signaling without systemic toxicity in mice. Science Signaling. 13(644). 13 indexed citations
4.
Restelli, Lisa Michelle, Mark Halliday, Cavit Ağca, et al.. (2018). Neuronal Mitochondrial Dysfunction Activates the Integrated Stress Response to Induce Fibroblast Growth Factor 21. Cell Reports. 24(6). 1407–1414. 77 indexed citations
5.
Halliday, Mark, Daniel T. Hughes, & Giovanna R. Mallucci. (2017). Fine‐tuning PERK signaling for neuroprotection. Journal of Neurochemistry. 142(6). 812–826. 49 indexed citations
6.
Hughes, Daniel T. & Mark Halliday. (2017). What Is Our Current Understanding of PrPSc-Associated Neurotoxicity and Its Molecular Underpinnings?. Pathogens. 6(4). 63–63. 17 indexed citations
7.
Halliday, Mark, Helois Radford, Colin Molloy, et al.. (2017). Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. Brain. 140(6). 1768–1783. 213 indexed citations
8.
Radford, Helois, Julie A. Moreno, Nicholas Verity, Mark Halliday, & Giovanna R. Mallucci. (2015). PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. Acta Neuropathologica. 130(5). 633–642. 222 indexed citations
9.
Halliday, Mark, Helois Radford, & Giovanna R. Mallucci. (2014). Prions: generation and spread versus neurotoxicity.. Apollo (University of Cambridge). 42 indexed citations
10.
Halliday, Mark & Giovanna R. Mallucci. (2014). Review: Modulating the unfolded protein response to prevent neurodegeneration and enhance memory. Neuropathology and Applied Neurobiology. 41(4). 414–427. 64 indexed citations
11.
Halliday, Mark & Giovanna R. Mallucci. (2013). Targeting the unfolded protein response in neurodegeneration: A new approach to therapy. Neuropharmacology. 76. 169–174. 98 indexed citations
12.
Moreno, Julie A., Mark Halliday, Colin Molloy, et al.. (2013). Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice. Science Translational Medicine. 5(206). 206ra138–206ra138. 453 indexed citations breakdown →
13.
Moreno, Julie A., Helois Radford, Diego Peretti, et al.. (2012). Sustained translational repression by eIF2α-P mediates prion neurodegeneration. Nature. 485(7399). 507–511. 489 indexed citations breakdown →
14.
Bhatti, Muhammad Iqbal, et al.. (2010). Castleman’s disease—A case report. International Journal of Surgery Case Reports. 1(3). 25–26. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Helois Radford Breakdown of academic impact, for papers by Nicholas Verity Breakdown of academic impact, for papers by Riccardo Cristofani Breakdown of academic impact, for papers by Rand Posmantur Breakdown of academic impact, for papers by John Labbadia Breakdown of academic impact, for papers by Cristina Caballero Breakdown of academic impact, for papers by Colin Molloy Breakdown of academic impact, for papers by Salvatore J. Cherra Breakdown of academic impact, for papers by Kie Itoh Breakdown of academic impact, for papers by Olaf Goldbaum
Rankless by CCL
2026